Head and Neck

This course highlights the best abstracts from Head and Neck Science:

  • Risk and Predictors of Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors treated with definitive radiotherapy: A Retrospective Cohort Study among 1,988 Survivors
  • Development of Advanced Preselection Tools to Reduce Unnecessary Plan Comparisons in Model-Based Selection of Head and Neck Cancer Patients for Proton Therapy
  • Defining Radiotherapy (RT) Coverage for Non-Melanoma Skin Cancer (NMSC) Using Mohs Micrographic Surgery (MMS) Margins
  • Nivolumab and ipilimumab combined with definitive radiation therapy in locally advanced squamous cell carcinoma of the head and neck: in-field toxicity analysis of a phase I clinical trial
  • Results of a randomized, open label, multicenter trial assessing the safety, dose and schedule of RRx-001 (R001) in reducing severe oral mucositis (SOM) in patients receiving chemoradiation (CRT) for oral cavity/oropharynx squamous cell carcinoma (OSCC)
  • Efficacy and Safety of Aprepitant for the Prevention of Nausea and Emesis during Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC): A Phase 2 Trial

 

Target Audience

The course is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, and all other health professionals involved in the field of radiation oncology.

Learning Objectives

Upon completion of this activity, learners should be able to do the following:

  • Identify the most relevant data, current recommendations, and ongoing controversies in the treatment of head and neck cancer.
  • Toxicity: Evaluate the extent of toxicity from head and neck cancer treatment and potential interventions to reduce this in the short- and long-term.
  • Multidisciplinary Treatment: Distinguish the best data on timing and type of systemic therapy for patients with head and neck cancer.
  • Skin Cancer: Employ best data to use in creation of skin cancer radiation plans.
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
01/01/2021
Course expires: 
12/31/2023
Cost:
$0.00
Parent activity set: 
Rating: 
0

Head and Neck
Beth Beadle, MD is employed by Stanford University and has no other disclosures to declare.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.